What question did this study set out to answer?

To evaluate the pharmacodynamic and antitumor efficacy of the novel synthetic Hsp90 inhibitor SNX-2112 and its oral prodrug SNX-5542 in HER kinase–dependent cancer models.

January 1, 2008Clinical Cancer Research

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

View Full Paper

Ask AI

Bookmark

Authors

SCSarat ChandarlapatyMemorial Sloan Kettering Cancer Center ASAyana SawaiMemorial Sloan Kettering Cancer Center QYQing YeKunming Medical University

Discussion

Member takes

Implication

Preclinical evaluation demonstrates potent antitumor activity and HER kinase degradation in xenograft models, highlighting a viable oral therapeutic strategy.

Key Points

To evaluate the pharmacodynamic and antitumor efficacy of the novel synthetic Hsp90 inhibitor SNX-2112 and its oral prodrug SNX-5542 in HER kinase–dependent cancer models.
Tested the effects of SNX-2112 and its prodrug SNX-5542 on client protein degradation, signaling pathways, cell cycle arrest, and apoptosis across a panel of tumor cell lines.
Assessed pharmacokinetic properties, tissue accumulation, and antitumor efficacy using daily oral administration of SNX-5542 in HER2-dependent and mutant EGFR non-small cell lung cancer xenograft mouse models.
SNX-2112 induced degradation of HER2 and mutant EGFR, blocked ERK and Akt activation, and triggered Rb-dependent G1 arrest and apoptosis in tumor cell lines.
Oral delivery of SNX-5542 resulted in rapid conversion to SNX-2112, high tumor-specific accumulation, HER2 degradation and pathway inhibition for up to 24 hours, and regression of HER2-dependent xenografts.
SNX-5542 exhibited greater in vivo antitumor efficacy than 17-AAG in a non-small cell lung cancer xenograft model expressing mutant EGFR.

Cite This Study

Chandarlapaty et al. (2008) studied this question.

synapsesocial.com/papers/6a769c6f98f24dbf64bd428f https://doi.org/10.1158/1078-0432.ccr-07-1667

View Full Paper

Ask AI

Bookmark

January 1, 2008Clinical Cancer Research

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

View Full Paper

Ask AI

Bookmark

Authors

SCSarat ChandarlapatyMemorial Sloan Kettering Cancer Center ASAyana SawaiMemorial Sloan Kettering Cancer Center QYQing YeKunming Medical University

Discussion

Member takes

Implication

Preclinical evaluation demonstrates potent antitumor activity and HER kinase degradation in xenograft models, highlighting a viable oral therapeutic strategy.

Key Points

To evaluate the pharmacodynamic and antitumor efficacy of the novel synthetic Hsp90 inhibitor SNX-2112 and its oral prodrug SNX-5542 in HER kinase–dependent cancer models.
Tested the effects of SNX-2112 and its prodrug SNX-5542 on client protein degradation, signaling pathways, cell cycle arrest, and apoptosis across a panel of tumor cell lines.
Assessed pharmacokinetic properties, tissue accumulation, and antitumor efficacy using daily oral administration of SNX-5542 in HER2-dependent and mutant EGFR non-small cell lung cancer xenograft mouse models.
SNX-2112 induced degradation of HER2 and mutant EGFR, blocked ERK and Akt activation, and triggered Rb-dependent G1 arrest and apoptosis in tumor cell lines.
Oral delivery of SNX-5542 resulted in rapid conversion to SNX-2112, high tumor-specific accumulation, HER2 degradation and pathway inhibition for up to 24 hours, and regression of HER2-dependent xenografts.
SNX-5542 exhibited greater in vivo antitumor efficacy than 17-AAG in a non-small cell lung cancer xenograft model expressing mutant EGFR.

Cite This Study

Chandarlapaty et al. (2008) studied this question.

synapsesocial.com/papers/6a769c6f98f24dbf64bd428f https://doi.org/10.1158/1078-0432.ccr-07-1667

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark